Avantogen Oncology Inc. (fka AVTO)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Renee

05/20/20 9:00 AM

Post #35

AVTO FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

Renee

05/13/19 9:38 AM

Post #34

AVTO SEC Suspension because of questions regarding the adequacy and accuracy of information about the company.

https://www.sec.gov/litigation/suspensions/2019/34-85835.pdf

Order:

https://www.sec.gov/litigation/suspensions/2019/34-85835-o.pdf

Aduke

07/15/16 2:12 PM

Post #33

AVTO - Someone must really want the shares - $0.020

xenod

01/10/14 5:12 PM

Post #32

AVTO, WOW!

SuperC

09/13/13 3:13 AM

Post #31

Re: #30: @Johnstown - AVTO 0055 NITE just finally moved off and

AVTO .0055 looking good here: http://investorshub.advfn.com/boards/msgsearch.aspx?searchstr=avto

and yes data suggests: wink http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=2259&i=AVTO&pv=recent-symbols&pp=AVTO#&&vs=635146517975272108

Johnstown

09/12/13 3:09 PM

Post #30

Re: #25: @SuperC - Thanks, personally don't think this was 'the-run', volume

AVTO 0055 NITE just finally moved off and 0075 is up 220k vol. today, maybe news soon

Troy Lando Free

07/25/13 6:59 AM

Post #28

AVTO is on the REH Sho List

Good day to hammer $AVTO

Its on the REG SHO sec threshold list

http://www.phlx.com/trader.aspx?id=RegSHOThreshold

lazyeye

07/19/13 11:46 AM

Post #27

lol..only on the pinks can a stock with no operations, no current T/A, no news and no prospects, a jailed former CEO and no current info rise 300% in a day on a pre-loaded pump.

Congrats to those of us who got out before it crashes and thanks to ALL of you for the weekend spending money woohoo!

Troy Lando Free

07/19/13 11:30 AM

Post #26

Re: #25: @SuperC - Thanks, personally don't think this was 'the-run', volume

I added it to watchlist... AVTO looks interesting

SuperC

07/19/13 11:29 AM

Post #25

Re: #21: @Troy Lando - 689% lol nice one GL SC

Thanks, personally don't think this was 'the-run', volume alarms went off for day traders, etc.

Let's see what happens next today, next week.. or ?

sc

ash qill

07/19/13 11:22 AM

Post #24

loving the volume!!

SuperC

07/19/13 11:17 AM

Post #23

Re: #22: @$treet Trader - yup/some group loaded

AVTO .0099 to many shares left on the table from an outside iHub buyer.... this run was quick but I don't think it has anything to do with the loading process. Could be wrong...

Looking for another move above .01 again

$treet Trader PremiumMember

07/19/13 11:10 AM

Post #22

Re: #20: @SuperC - AVTO 23.6 million that day and very little

yup/some group loaded

Troy Lando Free

07/19/13 11:09 AM

Post #21

Re: #19: @SuperC - AVTO pre-load big time, fresh play.... look out!

689% lol nice one GL SC

SuperC

07/19/13 11:07 AM

Post #20

Re: #18: @$treet Trader - AVTO .015 amazing/weeeeeeeeeeeeeeeee

AVTO 23.6 million that day and very little change... MM/Group Strategy Pre_Event Loading.

SuperC

07/19/13 11:06 AM

Post #19

Re: #17: @Troy Lando - Nice find gl here AVTO

AVTO pre-load big time, fresh play.... look out! http://investorshub.advfn.com/boards/msgsearch.aspx?searchstr=avto

http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=2259&i=AVTO&pv=recent-symbols&pp=AVTO

How dare someone pre-load, lol

$treet Trader PremiumMember

07/19/13 11:06 AM

Post #18

Re: #13: @SuperC - AVTO .01 on your .0015er weeeeeeeeeeeeee

AVTO .015 amazing/weeeeeeeeeeeeeeeee

Troy Lando Free

07/19/13 11:05 AM

Post #17

Re: #13: @SuperC - AVTO .01 on your .0015er weeeeeeeeeeeeee

Nice find gl here AVTO

Troy Lando Free

07/19/13 11:05 AM

Post #16

Re: #15: @Troy Lando - On radar AVTO

Can anyone fill me in

AVTO

Troy Lando Free

07/19/13 11:04 AM

Post #15

Re: #14: @Troy Lando - Mover here is it new? AVTO

On radar AVTO

Troy Lando Free

07/19/13 11:04 AM

Post #14

Mover here is it new? AVTO

SuperC

07/19/13 11:03 AM

Post #13

Re: #12: @$treet Trader - AVTO .008

AVTO .01 on your .0015er weeeeeeeeeeeeee

$treet Trader PremiumMember

07/19/13 11:02 AM

Post #12

Re: #11: @SuperC - AVTO on 7/09 someone knew of future event?

AVTO .008

SuperC

07/19/13 11:01 AM

Post #11

Re: #10: @$treet Trader - AVTO .008 up/wow

AVTO on 7/09 someone knew of future event? :) http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=2259&i=AVTO&pv=recent-symbols&pp=AVTO

$treet Trader PremiumMember

07/19/13 10:59 AM

Post #10

Re: #9: @SuperC - AVTO .006 strong move here

AVTO .008 up/wow

SuperC

07/19/13 10:58 AM

Post #9

Re: #8: @$treet Trader - in AVTO .0015

AVTO .006 strong move here

$treet Trader PremiumMember

07/09/13 11:09 AM

Post #8

in AVTO .0015

SuperC

07/09/13 9:42 AM

Post #7

Re: #6: @SuperC - AVTO .009 1 - 20k buy on-watch

AVTO .009 vol log http://investorshub.advfn.com/boards/msgsearch.aspx?searchstr=avto

SuperC

02/07/13 4:16 PM

Post #6

AVTO .009 1 - 20k buy on-watch http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=2259&i=AVTO&pv=recent-symbols&pp=AVTO#&&vs=634958682563721255

labdrinker Free

05/01/07 8:29 AM

Post #5

the volume jumped compared to the past, 74k is a mmonths worth.

labdrinker Free

05/01/07 8:25 AM

Post #4

Re: #3: @surf1944 - Bought some AVTO today, just to see if

looked good the first day. had to pay .30 to buy it. bought 500shrs. theres no float.

surf1944

04/30/07 3:52 PM

Post #3

Re: #2: @labdrinker - i might try it for a little bit.

Bought some AVTO today, just to see if it goes anywhere.

labdrinker Free

04/26/07 7:55 AM

Post #2

i might try it for a little bit. might take a while ,but could pay.
1.7m now 23m+roy later. come off the e.
i hope they will file. lol

surf1944

04/26/07 7:00 AM

Post #1

LOS ANGELES, CA--(MARKET WIRE)--Apr 26, 2007 -- Avantogen Oncology, Inc. (OTC BB:AVTOE.OB - News) today announced that it has signed an agreement with SciClone Pharmaceuticals, Inc. (NasdaqGM:SCLN - News) with respect to its lead drug candidate, RP101, for the treatment of pancreatic cancer.

Under the terms of the agreement, Avantogen Oncology and its wholly owned subsidiary, Resistys, Inc., assigned all of their rights to RP101 to SciClone in exchange for approximately $1.7 million in upfront fees, success-based regulatory and commercial payments of up to $23.3 million and royalties on future sales. The milestone and royalty payments will be shared with RESprotect GmbH, the owner of the intellectual property rights to RP101. SciClone will develop and commercialize RP101, initially in combination with gemcitabine, for the treatment of pancreatic cancer in the U.S. and Canada.

"We are delighted to sign this agreement with SciClone Pharmaceuticals. This will ensure the continued development of RP101, a program which we believe holds significant promise to produce a meaningful therapeutic for patients with advanced pancreatic cancer," said Chris Nowers, Chief Executive Officer of Avantogen Oncology, Inc.

Friedhelm Blobel, Ph.D., President and Chief Executive Officer of SciClone Pharmaceuticals, Inc., added, "We are excited to complete this agreement with Avantogen Oncology, Inc. We believe that RP101 has the potential to offer a new therapeutic regimen to pancreatic cancer patients, and we are committed to moving this program forward expeditiously."

"We are pleased with the level of cooperation that we have received from RESprotect and SciClone Pharmaceuticals in achieving what we believe is an agreement that provides meaningful incremental value for our shareholders," stated Dr. William Ardrey, Chairman of Avantogen Oncology, Inc.

About RP101

Standard chemotherapy typically offers patients with advanced pancreatic cancer a median survival of approximately 6 months. In contrast, two open label, multi-center, Phase 1 trials indicated that RP101 in combination with standard chemotherapy was associated with a median survival of approximately 14 months and 9 months, when compared to well matched historical control patients receiving standard chemotherapy alone.

Forward-Looking Statements

Statements contained in this press release that are not historical information are forward-looking within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from stated expectations. Such potential risks and uncertainties include, among others, the results of clinical trials, access to capital, the effectiveness and pace of current and future product development efforts, regulatory approvals, product demand and market acceptance, the impact of competitive products and other factors which may be identified from time to time in the company's SEC filings and other public announcements.

About Avantogen Oncology, Inc.

Avantogen Oncology is an international biotechnology company focused on developing potential product candidates in oncology.

Avantogen Oncology, Inc. is traded on the OTC Bulletin Board under the symbol AVTOE.OB.

For further information, visit www.avantogenoncology.com.

Contact:

Contact:
Chris Nowers,
Chief Executive Officer,
Avantogen Oncology, Inc.
2121 Avenue of the Stars,
Suite 2550,
Los Angeles,
CA 90067, USA
Tel: +1 310 277 2077
Email: Email Contact

Avantogen Oncology Inc. (fka AVTO)

Followers	2	Posters	12
Posts (Today)	0	Posts (Total)	35
Created	04/26/07	Type	Free
Moderators

http://www.avantogen.com/ http://finance.yahoo.com/q/h?s=AVTO.pk Avantogen Oncology, Inc., a biotechnology company, engages in the acquisition and development of compounds to treat various types of cancer. Its products include INOC-001, a chemo-resistance inhibitor, which is in extended Phase I/II trials in Germany. The company also conducts Phase III and final Phase I study for INOC-001 to test dose-escalation in patients with metastatic pancreatic cancer. In addition, it develops INOC-005, which is a preclinical efficacy testing completed chemical entity that would be used for the treatment of prostate cancer; and INOC-009, a preclinical testing completed product, which is a reformulation of an intravenous chemotherapeutic agent that treats various types of cancer, including breast, ovarian, and AIDS-related Kaposi's sarcoma. The company has a joint venture partnership in Resistys, Inc. to develop INOC-001; and an agreement with Prostagenics, LLC to develop and commercialize INOC-005. Avantogen Oncology was founded in 1986. It was formerly known as Innovate Oncology, Inc. and changed its name to Avantogen Oncology, Inc. in July 2006. The company is headquartered in Los Angeles, California. Avantogen Oncology, Inc. is a subsidiary of Avantogen Limited. Key Statistics

Gallery View 4: (Full Sto, MACD, Aroon8)

Board Info

Posts Today	0
Posts (Total)	35
Posters	12
Moderators

New Post

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Avantogen Oncology Inc. (fka AVTO)

Avantogen Oncology Inc. (fka AVTO)

Join the InvestorsHub Community

Avantogen Oncology Inc. (fka AVTO)

Board Info